Ascletis Pharma Inc.

Investors

Voluntary Announcement - Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-beta Agonist ASC41
2021-04-14
Voluntary Announcement - Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentation by the International Liver Congress 2021
2021-04-12
Grant of Share Options
2021-04-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
2021-04-07
Grant of Share Options
2021-03-31
2020 Annual Results
2021-03-30
Inside Information - Investment Escalation in the R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors and Proposed Initiation of a Pivotal Phase II Trial of ASC40 in Combination with Bevacizumab in Chinese Patients with First Relapse of High
2021-03-30
Notice of Board Meeting
2021-03-17
Voluntary Announcement - FASN Inhibitor ASC40 Demonstrates Positive Phase II Topline Clinical Results from China Cohort of Patients with NASH
2021-03-09
Change of Principal Place of Business in Hong Kong
2021-03-08

4

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号